Grace Therapeutics Reports $7.8M Net Loss; FDA Meeting Scheduled on GTx-104
The biopharma firm faces FDA manufacturing questions on its aneurysmal hemorrhage candidate but plans to resubmit after clarification meeting.
By the FiledFeed automated desk
This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.
The short version
Grace Therapeutics reported a net loss of $7.8 million for fiscal 2026, an improvement from $9.6 million the prior year, as it wound down its pivotal Phase 3 trial. The FDA issued a Complete Response Letter in April 2026 citing manufacturing and non-clinical issues with its GTx-104 candidate; the company has scheduled a Type A meeting with the FDA to clarify the path to resubmission.
Filing impact
Filing sentiment
Grace Therapeutics, a late-stage biopharma company developing GTx-104 for aneurysmal subarachnoid hemorrhage (aSAH), reported fiscal year 2026 results on June 18, 2026.
Financial Results
For the fiscal year ended March 31, 2026, Grace reported a net loss of $7.8 million, or $0.47 per share, down from a net loss of $9.6 million, or $0.79 per share, in the prior fiscal year.
Research and development expenses fell to $2.4 million from $9.5 million, a decrease of $7.1 million driven mainly by the close-out of its Phase 3 STRIVE-ON clinical trial in early 2026. General and administrative expenses rose to $8.7 million from $7.2 million, reflecting legal and due diligence costs related to strategic initiatives and increased pre-commercial planning.
Cash and cash equivalents stood at $17.0 million at March 31, 2026, down $5.1 million from $22.1 million a year earlier. The company said it believes its cash will be sufficient to sustain operations for at least 12 months.
FDA Regulatory Update
GTx-104, a novel injectable form of the drug nimodipine designed for intravenous infusion, received a Complete Response Letter (CRL) from the FDA on April 23, 2026. This is a rejection with guidance for resubmission, not approval.
The FDA cited items in the Chemistry, Manufacturing, and Controls (CMC) section—dealing with how the drug is made and tested—and the non-clinical section. Specifically, the FDA referenced additional testing timepoints for the commercial product, non-clinical toxicology assessments, and manufacturing practice deficiencies with the contract manufacturer. Notably, no clinical deficiencies were identified.
The company said it has scheduled a Type A meeting with the FDA to clarify the resubmission path and determine next steps. It expects to provide a regulatory update after receiving official meeting minutes.
Trial Data and Business Highlights
The Phase 3 STRIVE-ON trial data comparing GTx-104 to oral nimodipine showed that GTx-104 met its primary endpoint: patients who received GTx-104 had a 19% reduction in clinically significant hypotension (low blood pressure) compared to those on oral nimodipine (28% versus 35%). Secondary outcomes also favored GTx-104, including higher dose consistency—54% of GTx-104 patients maintained relative dose intensity of 95% or higher, compared to only 8% on oral nimodipine. Additionally, 29% more patients on GTx-104 had favorable functional outcomes at 90 days, with fewer ICU readmissions and shorter ICU and ventilator stays. Adverse events were comparable between the two treatment arms, and no new safety issues were identified.
The trial enrolled 50 patients receiving GTx-104 and 52 receiving oral nimodipine. Eight deaths occurred in the GTx-104 arm versus four in the oral nimodipine arm; the company stated no deaths were determined to be related to either drug and all were due to the severity of the underlying disease.
Phase 3 STRIVE-ON trial results were presented at five major medical conferences over the past twelve months, including the American Academy of Neurology and the Society of Critical Care Medicine.
Intellectual Property
In September 2025, the U.S. Patent and Trademark Office issued Patent No. 12,414,943, titled "Nimodipine Parenteral Administration," covering the IV dosing regimen used in the STRIVE-ON trial. The new patent extends intellectual property protection to 2043. Grace said it has established a multi-layered patent estate, including five patents on the composition of its nimodipine formulation providing protection through 2037.
GTx-104 has also received Orphan Drug Designation from the FDA, which provides seven years of market exclusivity in the United States if certain conditions are met upon NDA approval.
About the Disease
aSAH is bleeding in the space surrounding the brain, often caused by a ruptured brain aneurysm. It accounts for about 5% of all strokes and affects an estimated 42,500 U.S. hospital-treated patients annually. Current standard-of-care nimodipine treatment has not been meaningfully updated in more than 40 years.
Key facts
- Grace Therapeutics reported net loss of $7.8 million for fiscal year ended March 31, 2026, down from $9.6 million the prior year
- Loss per share was $0.47 compared to $0.79 in prior fiscal year
- R&D expenses decreased $7.1 million to $2.4 million due to close-out of Phase 3 STRIVE-ON trial in early 2026
- G&A expenses increased $1.5 million to $8.7 million, driven by legal, due diligence, and pre-commercial planning costs
- Cash and cash equivalents of $17.0 million at March 31, 2026, down $5.1 million from prior year
- FDA issued Complete Response Letter on April 23, 2026, citing CMC and non-clinical deficiencies with no clinical issues identified
- Type A meeting with FDA scheduled to clarify path to GTx-104 NDA resubmission
- Phase 3 STRIVE-ON trial enrolled 50 patients on GTx-104 and 52 on oral nimodipine
- GTx-104 met primary endpoint: 28% of GTx-104 patients versus 35% of oral nimodipine patients experienced clinically significant hypotension
- 54% of GTx-104 patients achieved relative dose intensity of 95% or higher versus 8% on oral nimodipine
- 29% more GTx-104 patients had favorable functional outcomes at 90 days
- Eight deaths in GTx-104 arm, four in oral nimodipine arm; none attributed to study drugs
- U.S. Patent No. 12,414,943 issued September 16, 2025, covering IV dosing regimen with protection through 2043
- Five patents cover composition of GTx-104 formulation with protection through 2037
- GTx-104 granted Orphan Drug Designation providing seven years of market exclusivity upon FDA approval
Why it matters
Grace Therapeutics is seeking FDA approval to market GTx-104 as the first meaningful innovation in aSAH treatment in over 40 years. While the Phase 3 trial data showed clinical benefit and safety, the FDA's Complete Response Letter creates regulatory uncertainty and delays approval. The company's path forward depends on successfully addressing manufacturing and non-clinical questions in a resubmission. With only $17 million in cash and the company burning roughly $5 million annually, the timeline to resolve FDA issues and reach approval—or a funding/partnership decision—is material to its viability. The scheduled Type A meeting will clarify whether these are routine manufacturing fixes or more complex hurdles.
Frequently asked
- Why did the FDA reject Grace Therapeutics' drug application?
- The FDA issued a Complete Response Letter on April 23, 2026, citing issues in how the drug is manufactured and tested (Chemistry, Manufacturing, and Controls section) and non-clinical toxicology assessments. The FDA also referenced manufacturing practice deficiencies with the contract manufacturer. However, no clinical or safety issues were identified.
- What were the results of the Phase 3 STRIVE-ON trial?
- The trial compared GTx-104 (an intravenous form of nimodipine) to oral nimodipine in 102 patients with aneurysmal subarachnoid hemorrhage. GTx-104 met its primary endpoint, reducing clinically significant low blood pressure by 19% compared to oral nimodipine (28% versus 35%). Secondary outcomes also favored GTx-104, including higher drug dose consistency and more favorable functional outcomes at 90 days. Eight deaths occurred in the GTx-104 arm versus four in the oral group; none were attributed to the drugs.
- How much cash does Grace Therapeutics have, and how long will it last?
- The company had $17.0 million in cash at March 31, 2026, down from $22.1 million a year earlier. The company said it believes this cash will be sufficient to sustain planned operations for at least 12 months from the filing date of June 18, 2026.
- What is the next regulatory step for GTx-104?
- Grace Therapeutics has scheduled a Type A meeting with the FDA to clarify the path forward for resubmitting its application. The company plans to address the FDA's cited manufacturing and non-clinical issues in a resubmission and expects to provide a regulatory update after receiving the official meeting minutes.
What the filing reported
- 2.02 Results of Operations & Financial Condition
- 9.01 Financial Statements & Exhibits
Source
Based on Grace Therapeutics, Inc.'s 8-K filed with the SEC on Jun 18, 2026. Read the original filing on SEC.gov ↗